Cardiovascular outcomes trials in type 2 diabetes: Time to include young adults
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Overall, young adults with type 2 diabetes have been underrepresented in most clinical studies to date”
From An Enhanced SMS Text Message–Based Support and Reminder Program for Young Adults With Type 2 Diabetes (TEXT2U): Randomized Controlled Trial (2021) · cites this paper as [16]
In the citing paper
“young adults remain substantially under-represented in diabetes research, particularly in clinical trials evaluating pharmacological interventions, lifestyle modifications, and diabetes remission strategies.21,22”
From Managing early-onset type 2 diabetes in the individual and at the population level (2025) · cites this paper as [22]
In the citing paper
“Developing specific recommendations is difficult due to the severe under-representation of young adults in clinical trials, 21,22 and where recommendations have been published, they have a low GRADE certainty of evidence.31,44”
From Managing early-onset type 2 diabetes in the individual and at the population level (2025) · cites this paper as [22]
In the citing paper
“For adults, deriving signals from existing drug trials is also problematic as, in most large randomised controlled cardiovascular outcome trials, the median age of recruitment is in the 5th or 6th decade. 19 , 41”
From Developing services to support the delivery of care to people with early‐onset type 2 diabetes (2022) · cites this paper as [41]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663 · cited 2×
“Meta-analyses of existing CVOTs could enable informative subgroup analyses of young adults with YOD, but people aged <40 years were excluded from most of these trials, and individual patient data are typically unavailable for such studies.(7,8) As the future of CVOTs continues to be debated, government regulators, ind…”
BackgroundMethodFord, I., & Norrie, J. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1510059 · Cited by 1,405 · cited 3×
“Adopting a pragmatic trial design, studies can be embedded in the clinical setting by selecting sites that have existing electronic medical records and disease registers to maximize recruitment and minimize costs.(1,10) Enhancing recruitment using email and social media tools is cheaper and often more effective than p…”
BackgroundThe UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
STEVENS, R. J., KOTHARI, V., ADLER, A. I., & STRATTON, I. M. (2001) · Clinical Science · doi:10.1042/cs20000335 · Cited by 1,084 · cited 4×
“2020;22:3–5. wileyonlinelibrary.com/journal/dom © 2019 John Wiley & Sons Ltd 3 outcomes.6 Furthermore, the use of cardiovascular events as the only clinical outcome may not fully reflect the multi-system burden of T2D nor the safety and efficacy profile of these medications.1 Sodium- glucose co-transporter-2 inhibitor…”
BackgroundInfluentialType 2 diabetes in adolescents and young adults
Lascar, N., Brown, J., Pattison, H., Barnett, A. H., Bailey, C. J., & Bellary, S. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30186-9 · Cited by 824 · cited 1×
“outcomes.(6) Furthermore, the use of cardiovascular events as the only clinical outcome may not fully reflect the multi-system burden of T2D nor the safety and efficacy profile of these medications.”
BackgroundSattar, N., Rawshani, A., Franzén, S., Rawshani, A., Svensson, A.-M., Rosengren, A., McGuire, D. K., Eliasson, B., & Gudbjörnsdottir, S. (2019) · Circulation · doi:10.1161/circulationaha.118.037885 · Cited by 555
Toyama, T., Neuen, B. L., Jun, M., Ohkuma, T., Neal, B., Jardine, M. J., Heerspink, H. L., Wong, M. G., Ninomiya, T., Wada, T., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13648 · Cited by 330 · cited 2×
“Meta-analyses of existing CVOTs could enable informative subgroup analyses of young adults with YOD, but people aged <40 years were excluded from most of these trials, and individual patient data are typically unavailable for such studies.(7,8) As the future of CVOTs continues to be debated, government regulators, ind…”
BackgroundMethodClifton, L., & Clifton, D. A. (2019) · Trials · doi:10.1186/s13063-018-3108-3 · Cited by 178
Research works printed but not linked: 8
- 10.7326/M18-1900 · DOI · Paper page
- 10.2337/dc18-1796 · DOI
- RISE Consortium, RISE Consortium Investigators, 2019, Effects of treatment of impaired glucose tolerance or recently diagnosed type 2 diabetes with metformin alone or in combination with insulin glargine on β‐cell function: comparison of responses in youth and adults, Diabetes, 68, 1670
- Center for Drug Evaluation and Research, 2008, Diabetes Mellitus — Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes, 8
- 10.1042/cs1010671 · DOI · Paper page
- 10.2196/mhealth.4530 · DOI · Paper page
- 10.1111/dom.13547 · DOI
- 10.1016/j.jadohealth.2013.08.017 · DOI · Paper page
Cited by
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives
Chan, J. C. N., Lim, L.-L., Wareham, N. J., Shaw, J. E., Orchard, T. J., Zhang, P., Lau, E. S. H., Eliasson, B., Kong, A. P. S., Ezzati, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32374-6 · Cited by 793
Self-citationCardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice
Lim, L.-L., Chow, E., & Chan, J. C. N. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00776-2 · Cited by 91
Self-citationManaging early-onset type 2 diabetes in the individual and at the population level
Misra, S., Khunti, K., Goyal, A., Gable, D., Armocida, B., Tandon, N., Sachdev, P., Wild, S. H., Hivert, M.-F., & Beran, D. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01067-0 · Cited by 47
Middleton, T., Constantino, M., McGill, M., D'Souza, M., Twigg, S. M., Wu, T., Thiagalingam, A., Chow, C., & Wong, J. (2021) · Journal of Medical Internet Research · doi:10.2196/27263 · Cited by 38
Developing services to support the delivery of care to people with early‐onset type 2 diabetes
Misra, S., Gable, D., Khunti, K., Barron, E., Young, B., Kar, P., & Valabhji, J. (2022) · Diabetic Medicine · doi:10.1111/dme.14927 · Cited by 23
Metadata
- Authors
- Ke, C., Shah, B. R., Luk, A. O., Di Ruggiero, E., & Chan, J. C. N.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2019-10-08
- Volume
- 22
- Issue
- 1
- Pages
- 3-5
- ISSN
- 1462-8902
- 1463-1326
- Cited by
- 30
- References
- 7
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiovascular outcomes trials in type 2 diabetes: Time to include young adults. https://app.cochat.ai/papers/10.1111/dom.13874
- The paper
- Ke, C., Shah, B. R., Luk, A. O., Di Ruggiero, E., & Chan, J. C. N. (2020). Cardiovascular outcomes trials in type 2 diabetes: Time to include young adults. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13874
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.